Investigating how a specific protein pathway responds to radiation exposure
A Non-Canonical IRAK1 Signaling Pathway Triggered by Ionizing Radiation
This study is looking at how a specific protein called IRAK1 helps cancer cells survive radiation treatment, and by understanding this better, we hope to find new ways to make radiation therapy more effective for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10981158 on NIH RePORTER |
What this research studies
This research explores a newly identified signaling pathway involving the IRAK1 protein that is activated by ionizing radiation. It aims to understand how this pathway contributes to cell survival and resistance to radiation therapy in cancer treatment. By studying this mechanism in both zebrafish and human cells, the research seeks to uncover potential therapeutic targets that could enhance the effectiveness of radiotherapy. Patients may benefit from insights gained about improving cancer treatment outcomes through better understanding of cellular responses to radiation.
Who could benefit from this research
Good fit: Ideal candidates for this research are cancer patients undergoing or considering radiation therapy.
Not a fit: Patients with non-cancerous conditions or those not receiving radiation therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved cancer therapies that enhance the effectiveness of radiation treatment.
How similar studies have performed: Other research has shown promising results in understanding similar signaling pathways, suggesting potential for success in this novel approach.
Where this research is happening
New York, United States
- Icahn School of Medicine at Mount Sinai — New York, United States (Active)
Researchers
- Principal investigator: Sidi, Samuel — Icahn School of Medicine at Mount Sinai
- Study coordinator: Sidi, Samuel
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.